• Mashup Score: 0
    Tofacitinib exhibits shorter timeline to initial clinical response in PsA vs. placebo - 2 year(s) ago

    Tofacitinib for psoriatic arthritis is efficacious in most patient-reported and clinical endpoints over time, and shows shorter initial and meaningful response times versus switching from placebo to the drug at month 3, noted researchers. “The efficacy and safety of oral tofacitinib 5 mg or 10mg twice daily (BID) or adalimumab (40mg administered subcutaneously once every 2weeks [Q2W]) have

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      Patients with active #PsoriaticArthritis who received @pfizer 's #Xeljanz experienced a shorter timeline to initial clinical response vs. placebo #RheumTwitter https://t.co/mtjf2Gz4f1

  • Mashup Score: 0
    Tofacitinib linked to higher cardiovascular, cancer risks than TNF inhibitors in RA - 2 year(s) ago

    Patients with rheumatoid arthritis who received tofacitinib demonstrated a greater risk for major adverse cardiovascular events and cancer than those treated with TNF inhibitors, according to data in The New England Journal of Medicine. In the study — a safety trial ordered by the FDA following reports of increased lipid levels and cancer incidence associated with tofacitinib (Xeljanz,

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      Incidences of major adverse #cardiovascular events and #cancer were higher among patients treated with #Xeljanz compared with TNF inhibitors, according to new data released today in @NEJM https://t.co/UjD1wgRlDa

  • Mashup Score: 3
    FDA approves Xeljanz for active ankylosing spondylitis - 2 year(s) ago

    The FDA has approved Xeljanz for the treatment of adults with active ankylosing spondylitis who have had an inadequate response, or intolerance to, TNF inhibitors, according to a Pfizer press release.The announcement marks the fifth indication for the drug, making it the first and only oral JAK inhibitor approved in the United States for five diseases, according to Pfizer. Xeljanz (tofacitinib)

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      The #FDA has approved #Xeljanz for the treatment of adults with active ankylosing spondylitis who have had an inadequate response, or intolerance to, TNF inhibitors, according to a @pfizer press release https://t.co/eENqbK0NvI

  • Mashup Score: 0
    High-Dose Tofacitinib Cuts Colectomy Rates For Acute Severe UC - 2 year(s) ago

    A regimen of three daily doses of tofacitinib (Xeljanz, Pfizer) slashed rates of colectomy by nearly 90% in patients admitted to the hospital for acute severe ulcerative colitis, researchers have found.

    Source: www.gastroendonews.com
    Categories: Gastroenterology, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of gastroendonews
      gastroendonews

      A regimen of 3 daily doses of tofacitinib slashed rates of colectomy by nearly 90% in patients admitted to the hospital for acute severe ulcerative colitis. https://t.co/HlzUfvSs2B @Dana_Lukin @WeillCornell #Xeljanz #tofacitinib #colitis #IBD

  • Mashup Score: 2
    FDA adds black box warning to JAK inhibitors; cites heart-related issues, cancer, death - 3 year(s) ago

    The FDA has called for additional warning labels on janus kinase inhibitors after a safety review found this class of medications was associated with an excess risk for serious heart-related events, cancer, blood clots and death. An alert was previously issued by the FDA in February about the risk for serious health-related problems and cancer linked to tofacitinib (Xeljanz, Pfizer) compared with

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      Despite #FDA black box warnings against #Xeljanz , #Olumiant and #Rinvoq Dr. Stanley Cohen @UTSWNews noted that these drugs "should still be an option with proper discussion of the benefits and risk" for young healthy patients at low risk for complications https://t.co/VQfVnVweqO https://t.co/zXRMsBfoFK

  • Mashup Score: 2
    FDA adds black box warning to JAK inhibitors; cites heart-related issues, cancer, death - 3 year(s) ago

    The FDA has called for additional warning labels on janus kinase inhibitors after a safety review found this class of medications was associated with an excess risk for serious heart-related events, cancer, blood clots and death. An alert was previously issued by the FDA in February about the risk for serious health-related problems and cancer linked to tofacitinib (Xeljanz, Pfizer) compared with

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      #Rheumatologists and their patients took another hit this week after the #FDA slapped #Olumiant #Rinvoq and #Xeljanz with a new Boxed Warning. Dr. Andrew Laster @DukeU @UNC_SOM discusses how this complicates matters given the current #Actemra #shortage https://t.co/VQfVnVweqO

  • Mashup Score: 0
    'We need to see the data': FDA's Xeljanz safety warning stirs concerns for JAK inhibitors - 3 year(s) ago

    For Pfizer and its JAK inhibitor, Xeljanz, February rang in with the sound of alarm bells, as the FDA issued its third warning about the drug in 2 years. In this latest alert regarding tofacitinib, the FDA warned providers of an increased risk for serious heart-related issues and cancer among older patients, compared with TNF inhibitors.This has left many experts anxious to dig into the full

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      The #Xeljanz safety scare has raised some notable #cancer and #cardiovascular risks linked to #JAK inhibitor use. @HealioRheum sat down with #rheumatology experts to discuss the possible severity of these risks #RheumTwitter https://t.co/FPCXpddsVM

  • Mashup Score: 0
    'We need to see the data': FDA's Xeljanz safety warning stirs concerns for JAK inhibitors - 3 year(s) ago

    For Pfizer and its JAK inhibitor, Xeljanz, February rang in with the sound of alarm bells, as the FDA issued its third warning about the drug in 2 years. In this latest alert regarding tofacitinib, the FDA warned providers of an increased risk for serious heart-related issues and cancer among older patients, compared with TNF inhibitors.This has left many experts anxious to dig into the full

    Source: www.healio.com
    Categories: Latest Headlines, Rheumatology
    Tweet Tweets with this article
    • Profile photo of HealioRheum
      HealioRheum

      The recent #Xeljanz safety scare casts a long shadow on other #JAK inhibitors - @HealioRheum sat down with experts to discuss the possibility that other JAK inhibitors might share these #cancer and #cardiovascular risks #RheumTwitter #Rheumatology https://t.co/J25EuACrYH https://t.co/7p8hR28MBV

Load More